Dr. Makary Emphasizes AI in the FDA With tech
Post# of 60

With technologies like Optical Genome Mapping (OGM) proving their scientific and clinical merit, AI-driven evaluation systems could ensure objective assessments that rely strictly on current research and proven successes—not on outdated standards or industry politics. The more AI integrates into medical decision-making, the harder it will be for human bias to override the facts.
With the FDA’s AI actively synthesizing global research, backed by Microsoft’s extensive medical database, and leading institutions like Johns Hopkins and MD Anderson Cancer Center championing Optical Genome Mapping (OGM), the momentum for rapid adoption is undeniable.

